BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元

路透中文

Oct 06

BRIEF-<a href="https://laohu8.com/S/01177">中国生物制药</a>公司轩竹<a href="https://laohu8.com/S/000504">生物</a>拟在香港IPO筹7.8亿港元

路透香港10月6日 - 中国生物制药公司--轩竹生物科技股份有限公司2575.HK：

* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为中金公司

* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂$(PPI)$）、XZP-3287（已获NDA批准的靶向乳腺癌的细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂）和XZP-3621（已获NDA批准的靶向非小细胞肺癌(NSCLC)的间变性淋巴瘤激酶$(ALK)$抑制剂）

* 四环医药0460.HK透过其间接全资附属公司轩竹医药及海南四环于本公司全部已发行股本中拥有约56.47%权益；紧随全球发售完成后于已发行股份中拥有约49.13%的间接权益，本公司将仍为四环医药的间接非全资附属公司

欲览详情，请点击此处

(Reporting By Alison Lui)

((alison.lui@thomsonreuters.com; +852 3462 7749;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573647851"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573647851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573647851?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-06 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573647851","market":"us","top_or_hot":-1,"title":"BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>公司轩竹<a href=\"https://laohu8.com/S/000504\">生物</a>拟在香港IPO筹7.8亿港元</title></head><body><p><span>路透香港10月6日</span><span> - </span>中国生物制药公司--轩竹生物科技股份有限公司<span>2575.HK</span>：</p><p>* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为<a href=\"https://laohu8.com/S/601995\">中金公司</a></p><p>* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂<a href=\"https://laohu8.com/S/PPI\">$(PPI)$</a>）、XZP-3287（已获NDA批准的靶向乳腺癌的细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂）和XZP-3621（已获NDA批准的靶向非小细胞肺癌(NSCLC)的间变性淋巴瘤激酶<a href=\"https://laohu8.com/S/ALK\">$(ALK)$</a>抑制剂）</p><p>* <a href=\"https://laohu8.com/S/00460\">四环医药</a><span>0460.HK</span>透过其间接全资附属公司轩竹医药及海南<a href=\"https://laohu8.com/S/000518\">四环</a>于本公司全部已发行股本中拥有约56.47%权益；紧随全球发售完成后于已发行股份中拥有约49.13%的间接权益，本公司将仍为四环医药的间接非全资附属公司</p><p>欲览详情，请点击此处 </p><p> (Reporting By Alison Lui)</p><p> ((alison.lui@thomsonreuters.com; +852 3462 7749;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-10-06 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>公司轩竹<a href=\"https://laohu8.com/S/000504\">生物</a>拟在香港IPO筹7.8亿港元</title></head><body><p><span>路透香港10月6日</span><span> - </span>中国生物制药公司--轩竹生物科技股份有限公司<span>2575.HK</span>：</p><p>* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为<a href=\"https://laohu8.com/S/601995\">中金公司</a></p><p>* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂<a href=\"https://laohu8.com/S/PPI\">$(PPI)$</a>）、XZP-3287（已获NDA批准的靶向乳腺癌的细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂）和XZP-3621（已获NDA批准的靶向非小细胞肺癌(NSCLC)的间变性淋巴瘤激酶<a href=\"https://laohu8.com/S/ALK\">$(ALK)$</a>抑制剂）</p><p>* <a href=\"https://laohu8.com/S/00460\">四环医药</a><span>0460.HK</span>透过其间接全资附属公司轩竹医药及海南<a href=\"https://laohu8.com/S/000518\">四环</a>于本公司全部已发行股本中拥有约56.47%权益；紧随全球发售完成后于已发行股份中拥有约49.13%的间接权益，本公司将仍为四环医药的间接非全资附属公司</p><p>欲览详情，请点击此处 </p><p> (Reporting By Alison Lui)</p><p> ((alison.lui@thomsonreuters.com; +852 3462 7749;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nL3T3VN01K:1","article_id":"2573647851","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573647851","pubTimestamp":1759712526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元路透香港10月6日 - 中国生物制药公司--轩竹生物科技股份有限公司2575.HK：* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为中金公司* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂(PPI)","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00460":"四环医药","BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","BK1600":"工业大麻","02575":"轩竹生物-B"},"translate_title":"BRIEF-Chinese biopharmaceutical company Xuanzhu Biotech plans to raise HK $780 million in Hong Kong IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9,"02575":0.9},"content_text":"BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元路透香港10月6日 - 中国生物制药公司--轩竹生物科技股份有限公司2575.HK：* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为中金公司* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂$(PPI)$）、XZP-3287（已获NDA批准的靶向乳腺癌的细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂）和XZP-3621（已获NDA批准的靶向非小细胞肺癌(NSCLC)的间变性淋巴瘤激酶$(ALK)$抑制剂）* 四环医药0460.HK透过其间接全资附属公司轩竹医药及海南四环于本公司全部已发行股本中拥有约56.47%权益；紧随全球发售完成后于已发行股份中拥有约49.13%的间接权益，本公司将仍为四环医药的间接非全资附属公司欲览详情，请点击此处  (Reporting By Alison Lui) ((alison.lui@thomsonreuters.com; +852 3462 7749;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}